A new Pompe disease therapy has been approved by the European Medicines Agency, with Amicus Therapeutics (Nasdaq: FOLD) picking up authorization for the enzyme stabilizer Opfolda (miglustat).
The marketing nod allows Amicus to offer the medicine, together with the previously-approved Pombiliti (cipaglucosidase alfa), for adults with late-onset Pompe disease.
Pompe disease is an inherited lysosomal disorder caused by deficiency of a certain enzyme acid. The late-onset form affects skeletal muscle and respiratory function.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze